Glyburide increases the secretion, tissue uptake, and action of insulin in conscious normal dogs

Metabolism: Clinical and Experimental

Volumn 45, Issue 5, 1996, Pages 579-586

  Adrogué, Horacio J ^a   Peña, James ^b   Comstock, John P ^b  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLUCAGON; GLUCOSE; INSULIN;

ANIMAL EXPERIMENT; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DOG; FEMALE; HORMONE ACTION; HORMONE TRANSPORT; INSULIN INFUSION; INSULIN RELEASE; INTRAVENOUS GLUCOSE TOLERANCE TEST; LIVER; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0029919701     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(96)90027-X     Document Type: Article

References (31)

1. Gerich JE: Oral hypoglycemic agents. N Engl J Med 321:1231-1245, 1989
2. Chen H, Hamel FG, Siford G, Duckworth WC: Alteration of rat hepatic insulin metabolism by glyburide and glipizide. J Pharmacol Exp Ther 264:1293-1298, 1993
3. Aimer LO, Johansson E, Melander A, et al: Influence of sulphonylureas on the secretion, disposal and effect of insulin. Eur J Clin Pharmacol 22:27-32, 1982
4. Gavin JR III: Glyburide: New insights into its effects on the beta cell and beyond - Introduction. Am J Med 89:1S-2S, 1990 (suppl 2A)
5. Porte D Jr, Kahn SE: Mechanisms for hyperglycemia in type II diabetes mellitus: Therapeutic implications for sulfonylurea treatment - An update. Am J Med 90:8S-14S, 1991 (suppl 6A)
6. Scheen AJ, Lefebvre PJ, Luyckx AS: Glipizide increases plasma insulin but not C-peptide level after a standardized breakfast in type 2 diabetic patients. Eur J Clin Pharmacol 26:471-474, 1984
7. Beck-Nielsen H, Hother-Nielsen O, Andersen PH, et al: In vivo action of glibenclamide. Diabetologia 29:515A, 1986 (abstr)
8. Groop L, Luzi L, Melander A, et al: Different effects of glyburide and glipizide on insulin secretion and hepatic glucose production in normal and NIDDM subjects. Diabetes 36:1320-1328, 1987
9. Melander A, Lebovitz HE, Faber OK: Sulfonylureas. Why, which, and how? Diabetes Care 13:18-25, 1990 (suppl 3)
10. Adrogué HJ, Chap Z, Okuda Y, et al: Acidosis-induced glucose intolerance is not prevented by adrenergic blockade. Am J Physiol 225:E812-E823, 1988
11. Adrogué HJ: Nephrology Forum: Glucose homeostasis and the kidney. Kidney Int 42:1266-1282, 1992
12. Adrogué HJ, Chap Z, Ishida T, et al: Role of the endocrine pancreas in the kalemic response to acute metabolic acidosis in conscious dogs. J Clin Invest 75:798-808, 1985
13. Herbert V, Lau KS, Gottlieb CW, et al: Coated charcoal immunoassay of insulin. J Clin Endocrinol Metab 25:1375-1379, 1965
14. Faloona GR, Unger RH: Glucagon, in Jaffe BM, Berman HR (eds): Methods of Hormone Radioimmunoassay. New York, NY, Academic, 1974, pp 317-330
15. Gottesman I, Mandarino L, Gerich J: Use of glucose uptake and glucose clearance for the evaluation of insulin action in vivo. Diabetes 33:184-191, 1984
16. Kolterman OG: The impact of sulfonylureas on hepatic glucose metabolism in type II diabetics. Diabetes Metab Rev 3:399-414, 1987
17. Beck-Nielsen H, Hother-Nielsen O, Pedersen O: Mechanism of action of sulphonylureas with special reference to the extrapancreatic effect: An overview. Diabetic Med 5:613-620, 1988
18. Del Prato S, Vigili de Kreutzenberg S, Riccio A, et al: Hepatic sensitivity to insulin: Effects of sulfonylurea drugs. Am J Med 90:29S-36S, 1991 (suppl 6A)
19. Adrogué HJ, Pena J, Comstock JP: Enhanced hepatic extraction of insulin (HExI) and glucagon (HExGn) by chronic glyburide therapy in normal dogs. Clin Res 39:445A, 1991 (abstr)
20. Feinglos MN, Lebovitz HE: Sulphonylureas increase the number of insulin receptors. Nature 276:184-185, 1978
21. Bachmann W, Bottger I, Haslbeck M, et al: Extrapancreatic action of sulphonylureas: Effect of gliquidone on insulin and glucagon binding to rat liver plasma membranes. Eur J Clin Invest 9:411-415, 1979
22. Greenstein BD: Improved insulin receptor assay: Effects of an antidiabetic sulfonylurea on liver membrane insulin receptors from obese hyperglycemic mice. Br J Pharmacol 66:317-322, 1979
23. Dolais-Kitabgi J, Alengrin F, Freychet P: Sulphonylureas in vitro do not alter insulin binding or insulin effect on amino acid transport in rat hepatocytes. Diabetologia 24:441-444, 1983
24. Nowak SM, McCaleb ML, Lockwood DH: Extrapancreatic action of sulfonylurea: Hypoglycemic effects are not dependent on altered insulin binding or inhibition of transglutaminase. Metabolism 32:398-402, 1983
25. Salhanick AI, Konowitz P, Amatruda JM: Potentiation of insulin action by a sulfonylurea in primary cultures of hepatocytes from normal and diabetic rats. Diabetes 32:206-212, 1983
26. Fleig W, Noether-Fleig G, Fussgaenger R, et al: Modulation by a sulfonylurea of insulin-dependent glycogenesis, but not of insulin binding, in cultured hepatocytes. Evidence for a postreceptor mechanism of action. Diabetes 33:285-290, 1984
27. Davidson MB, Sladen G: Effect of glyburide on glycogen metabolism in cultured rat hepatocytes. Metabolism 36:925-930, 1987
28. Wardzala LJ, Hirshman M, Pofcher E, et al: Regulation of glucose utilization in adipose cells and muscle after long-term experimental hyperinsulinemia in rats. J Clin Invest 76:460-469, 1985
29. Rizza RA, Mandarino LJ, Genest J, et al: Production of insulin resistance by hyperinsulinaemia in man. Diabetologia 28:70-75, 1985
30. McGuinness OP, Myers SR, Neal D, et al: Chronic hyperinsulinemia decreases insulin action but not insulin sensitivity. Metabolism 39:931-937, 1990
31. + channels in the modulation of vascular smooth muscle tone, in Cook NS (ed): Potassium Channels. New York, NY, Wiley, 1990, pp 259-299